Strongbridge Biopharma (SBBP) Stock Price, News & Analysis

Company Overview

Strongbridge Biopharma Plc operates as a commercial-stage biopharmaceutical company, which focuses on the development and commercialization of therapies for rare diseases. Its pipeline is comprised of Keveyis, Macrilen, Recorlev, and Veldoreotide. The company was founded in 1996 and is headquartered in Trevose, PA.

Key Stats

• Today's Range: $1.95 to $2.06
• 50-Day Range: $1.89 to $2.29
• 52-Week Range: $1.85 to $4.26
• Volume: 684,684 shs
• Average Volume: 866,464 shs
• Market Capitalization: $135.66 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

SBBP Stock Analysis - Frequently Asked Questions

How were Strongbridge Biopharma's earnings last quarter?

Strongbridge Biopharma plc (NASDAQ:SBBP) posted its quarterly earnings results on Thursday, August, 5th. The biotechnology company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.12) by $0.09. The biotechnology company earned $10.04 million during the quarter, compared to analysts' expectations of $8.83 million. Strongbridge Biopharma had a negative net margin of 115.67% and a negative trailing twelve-month return on equity of 66.82%.

What other stocks do shareholders of Strongbridge Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Strongbridge Biopharma investors own include Energy Transfer (ET), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), OPKO Health (OPK) and Viking Therapeutics (VKTX).

Company Calendar

• Last Earnings: 8/05/2021
• Today: 9/06/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:SBBP
• CIK: 1634432
• Web: www.strongbridgebio.com
• Phone: (610) 254-9200
• Fax: N/A
• Employees: 72
• Year Founded: 1996

Profitability

• EPS (Trailing Twelve Months): ($0.78)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$45.08 million
• Net Margins: -115.67%
• Pretax Margin: N/A
• Return on Equity: -66.82%
• Return on Assets: -36.21%

Debt

• Debt-to-Equity Ratio: 0.38
• Current Ratio: 3.00
• Quick Ratio: 2.95

Sales & Book Value

• Annual Sales: $30.73 million
• Price / Sales: 4.41
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.98 per share
• Price / Book: 2.04

Miscellaneous

• Outstanding Shares: 67,829,000
• Free Float: N/A
• Market Cap: $135.66 million
• Optionable: Optionable
• Beta: 1.58